Trial
NCT04720664
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Georgetown University
Collaborators
Tyme, Inc
Condition
Breast Cancer
Intervention
SM-88
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-28